We examined data from a Phase @ trial -LCB- NCT@ -RCB- of ivacaftor , a CFTR potentiator , in cystic fibrosis ( CF ) patients with aG@D mutation to evaluate standardized approaches to sweat chloride measurement and to explore the use of sweat chloride and nasal potential difference ( NPD ) to estimate CFTR activity .